Tag Archive for: Real-Time Oncology Review (RTOR) pilot program

Servier today announced that the U.S. Food and Drug Administration approved TIBSOVO (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.